- Home
- ECVT vs DNTH Comparison
ECVT vs DNTH Comparison
Compare ECVT & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECVT
- DNTH
- Stock Information
- Founded
- ECVT 1935
- DNTH 2015
- Country
- ECVT United States
- DNTH United States
- Employees
- ECVT N/A
- DNTH N/A
- Industry
- ECVT Major Chemicals
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ECVT Industrials
- DNTH Health Care
- Exchange
- ECVT Nasdaq
- DNTH Nasdaq
- Market Cap
- ECVT 1.0B
- DNTH 1.0B
- IPO Year
- ECVT 2017
- DNTH N/A
- Fundamental
- Price
- ECVT $9.05
- DNTH $37.08
- Analyst Decision
- ECVT Strong Buy
- DNTH Strong Buy
- Analyst Count
- ECVT 3
- DNTH 8
- Target Price
- ECVT $10.00
- DNTH $60.67
- AVG Volume (30 Days)
- ECVT 1.3M
- DNTH 894.0K
- Earning Date
- ECVT 10-30-2025
- DNTH 11-06-2025
- Dividend Yield
- ECVT N/A
- DNTH N/A
- EPS Growth
- ECVT N/A
- DNTH N/A
- EPS
- ECVT N/A
- DNTH N/A
- Revenue
- ECVT $723,462,000.00
- DNTH $4,854,000.00
- Revenue This Year
- ECVT $16.62
- DNTH N/A
- Revenue Next Year
- ECVT $6.11
- DNTH N/A
- P/E Ratio
- ECVT N/A
- DNTH N/A
- Revenue Growth
- ECVT 4.93
- DNTH 17.87
- 52 Week Low
- ECVT $5.24
- DNTH $13.37
- 52 Week High
- ECVT $9.69
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- ECVT 53.21
- DNTH 83.10
- Support Level
- ECVT $8.90
- DNTH $22.81
- Resistance Level
- ECVT $9.69
- DNTH $24.81
- Average True Range (ATR)
- ECVT 0.24
- DNTH 2.63
- MACD
- ECVT -0.01
- DNTH 1.45
- Stochastic Oscillator
- ECVT 27.53
- DNTH 90.43
About ECVT Ecovyst Inc.
Ecovyst Inc is an integrated and provider of materials, specialty catalysts and services. Its products contribute to lower emissions and cleaner air, higher fuel efficiency and cleaner fuels, and key enablers to advance transition to clean energy. The company has two reporting segments: Ecoservices and Advanced Materials & Catalysts. Ecoservices provides sulfuric acid recycling to the North American refining industry for the production of alkylate and provides on-purpose virgin sulfuric acid for water treatment, mining, and industrial applications. Maximum revenue is generated from Ecoservices segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.